Guided Bone Regeneration Using Fixed vs Non-Fixed Resorbable Collagen Membranes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversitat Internacional de Catalunya

About this trial

The aim of this clinical trial is to compare the horizontal bone gain when grafting a bone substitute with non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring Guided Bone Regeneration (GBR) to facilitate implant placement at 6 months.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Men and women over 18 years old or older

Patients requiring Guided Bone Regeneration due to insufficient ridge width(≤5mm) to place dental implants, with sufficient vertical ridge height (≥9mm) from vital anatomical structures (the inferior alveolar nerve in the Mandible, or the sinus in the Maxilla)

One or more teeth missing in posterior zone (Premolars, and Molars)

Absence of active Periodontal disease

Disqualifiers

Patients with sufficient ridge width (>5 mm) and height (≥9mm) from vital anatomical structure) requiring no GBR to place dental implants

Patients with severe horizontal and vertical defects requiring other surgical techniques.

Long-term non-steroidal anti-inflammatory drug therapy (3months).

Lactating females or currently pregnant women.

Trial design

Design model

Factorial

Treatments tested in this trial

  • Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane

    Procedure/Surgery

    Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).

  • Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane

    Procedure/Surgery

    Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).

Treatment groups

26 Participants
are divided into 2 treatment groups
Group A: Control GroupExperimental treatment 1 intervention
Group B: Test GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Horizontal Bone Gain

To compare the horizontal bone gain when grafting a mixture of xenograft and allograft (50/50) with non-fixed resorbable collagen membranes (control group) versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring GBR to facilitate implant placement at 6 months. Along the 6 months, 3 Cone Beam Computed Tomography scans (CBCT) will be needed. At baseline (T1), the first CBCT will be taken before performing any surgical procedure to measure the initial width of the ridge. Immediately after the GBR (T2), a second CBCT scan will be taken, which will be useful to measure new ridge width in each group. Finally, at 6 month follow-up a third CBCT scan will be taken (T3) in order to assess the difference with T1 regarding amount of bone gain horizontally, and with T2 regarding horizontal dimensional stability of the grafted bone in each of the 2 groups.

Time frame
T3: 6 months after the Horizontal GBR
2

Bone Width Gain

To compare the bone width gain between the test group and control group, 6 months after the horizontal GBR. A caliper will be used in order to evaluate and compare the bone width gain at T1, T2, and T3 between the Test and Control Groups. These measurements are performed intra-operatively before the Horizontal GBR (T1), immediately after (T2), and at 6 months (T3) at the time of implant placement. Measurements will be performed at 1cm, 3cm, and 5cm apical from the bone crest at the regenerated area.

Time frame
T3: 6 months after the Horizontal GBR

Secondary outcomes

1

Horizontal Dimensional Stability

To compare the horizontal dimensional stability of the augmented ridges between the test group and control group after 6 months. After the surgical procedure, a CBCT scan (T2) will be completed and the bone width will be assessed and compared with the bone width at 6 months postoperatively when a new CBCT scan (T3) will be completed before implant placement.

Time frame
T3: 6 months after the Horizontal GBR
2

Post-surgical complications

To compare the post-surgical complications that may occur between the test group and control group throughout the period of healing and during the following 6 months. The complications will be evaluated using the Healing Complications Classification, as suggested by Fontana et al. 2011. The healing post-surgical complications are divided into four classes, according to the presence and extent of exposure, as well as the presence of a purulent exudate: * Class I: membrane exposure \<3mm, no purulent exudate * Class II: membrane exposure ≥3mm, no purulent exudate * Class III: membrane exposure with purulent exudate * Class IV: abscess, without membrane exposure

Time frame
T2-T3: From the surgery to 6 months
3

Patient's satisfaction

To compare patient's satisfaction regarding the post-operative pain and compare it between the test group and control group throughout the period of healing and during the following 6 months, through the use of a Visual Analogue Scale (VAS). It is a 10cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patients will be asked to mark their average experience of discomfort and pain. The scores of the VAS will be obtained by measuring the distance in centimeters (0 to 10).

Time frame
At 2-weeks follow up after the surgical procedure
4

Histologic examination of the augmented bone at 6 months

To examine type of cells present after 6 months of procedure by performing histological examination to the sample harvested from the site with the use of an implant trephine drill. The histologic evaluation will be performed in order to evaluate the type of cells present at the site of augmentation

Time frame
At time of implant placement

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.